FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885223211> ?p ?o ?g. }

• W2885223211 abstract "Sulindac has been shown in clinical trials to reduce the number and size of precancerous colon adenomas, but is not recommended for the long-term management of polyposis syndromes because of potentially fatal toxicities resulting from cyclooxygenase (COX) inhibition and the suppression of prostaglandin synthesis. Here we characterize the activity of a non-COX inhibitory sulindac derivative, MCI-030, that inhibits a novel cancer target, phosphodiesterase 10A (PDE10), recently reported to be overexpressed in colon tumors and essential for tumor cell growth (Oncogene 34:1499-509, 2015). PDE10 is an attractive cancer target because of limited expression and no known function in normal peripheral tissues. MCI-030 potently and selectively inhibits the growth of multiple colon tumor cell lines expressing PDE10 with IC50 values of 0.3 μM, but does not affect the growth of normal colonocytes (NCM460) that do not express PDE10. Sulindac inhibits colon tumor cell growth with IC50 values approximately 200 fold higher and modest tumor cell selectivity. MCI-030 is PDE10 selective, but sulindac inhibits multiple PDE isozymes (PDE2, 3, 5, and 10). MCI-030 treatment of colon tumor cells increased intracellular cGMP levels and activated protein kinase G at concentrations that inhibit recombinant PDE10 and tumor cell growth. Inhibition of PDE10 by MCI-030 or siRNA increased the phosphorylation and degradation of β-catenin and inhibited Wnt-induced nuclear translocation to suppress TCF-mediated transcription of cyclin D and survivin, leading to cell cycle arrest and apoptosis. With attractive pharmacokinetics and ability to achieve high concentrations in colon mucosa following oral administration, MCI-030 was tested in the APC+/min-FCCC mouse model of colon tumorigenesis. At 7-8 weeks of age, mice endoscopically determined to be adenoma-free were assigned to receive either control or MCI-030 supplemented diet (1500ppm) for 14 weeks. MCI-030 reduced the multiplicity of colonic adenomas by 50% (control: 3.95 ± 0.81 vs. MCI-030: 1.95 ± 0.58, P < 0.05) and incidence by 36.7%. MCI-030 also reduced the multiplicity of polypoid adenomas (36%), microadenomas (69%), and flat adenomas (100%, P < 0.05). These data indicate that MCI-030 strongly inhibits tumorigenesis in a predictive preclinical mouse model of colorectal cancer without discernable toxicity and could be effective together with colonoscopy in humans to reduce polyp formation and prevent malignant progression. In addition, in vitro colony formation and transformation assays using human colon tumor cells showed benefits of combining MCI-030 with the ornithine decarboxylase inhibitor, DFMO, supporting testing of this novel combination in the APC+/min-FCCC mouse model as a strategy to further improve efficacy. Funding from NCI R01CA131378, R01CA148817, R01CA197147, and R01CA155638.Citation Format: Gary A. Piazza, Ashleigh Neese, Kevin Lee, Adam Keeton, Yulia Maxuitenko, Veronica Ramirez Alcantara, Kristy Berry, Jacob Valiyaveettil, Antonio Ward, Luciana Madeira da Silva, Jennifer Scalici, Bing Zhu, Tyler Mattox, Xi Chen, Margie Clapper, Harry Cooper, Wen-Chi Chang. Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1937." @default.
• W2885223211 created "2018-08-22" @default.
• W2885223211 creator A5006292933 @default.
• W2885223211 creator A5008171524 @default.
• W2885223211 creator A5008726864 @default.
• W2885223211 creator A5021533593 @default.
• W2885223211 creator A5022569332 @default.
• W2885223211 creator A5025773119 @default.
• W2885223211 creator A5027780619 @default.
• W2885223211 creator A5034358215 @default.
• W2885223211 creator A5036693985 @default.
• W2885223211 creator A5037915403 @default.
• W2885223211 creator A5038464425 @default.
• W2885223211 creator A5046535820 @default.
• W2885223211 creator A5062264366 @default.
• W2885223211 creator A5071802884 @default.
• W2885223211 creator A5086841234 @default.
• W2885223211 creator A5089028589 @default.
• W2885223211 creator A5090126068 @default.
• W2885223211 date "2018-07-01" @default.
• W2885223211 modified "2023-10-15" @default.
• W2885223211 title "Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors" @default.
• W2885223211 doi "https://doi.org/10.1158/1538-7445.am2018-1937" @default.
• W2885223211 hasPublicationYear "2018" @default.
• W2885223211 type Work @default.
• W2885223211 sameAs 2885223211 @default.
• W2885223211 citedByCount "0" @default.
• W2885223211 crossrefType "proceedings-article" @default.
• W2885223211 hasAuthorship W2885223211A5006292933 @default.
• W2885223211 hasAuthorship W2885223211A5008171524 @default.
• W2885223211 hasAuthorship W2885223211A5008726864 @default.
• W2885223211 hasAuthorship W2885223211A5021533593 @default.
• W2885223211 hasAuthorship W2885223211A5022569332 @default.
• W2885223211 hasAuthorship W2885223211A5025773119 @default.
• W2885223211 hasAuthorship W2885223211A5027780619 @default.
• W2885223211 hasAuthorship W2885223211A5034358215 @default.
• W2885223211 hasAuthorship W2885223211A5036693985 @default.
• W2885223211 hasAuthorship W2885223211A5037915403 @default.
• W2885223211 hasAuthorship W2885223211A5038464425 @default.
• W2885223211 hasAuthorship W2885223211A5046535820 @default.
• W2885223211 hasAuthorship W2885223211A5062264366 @default.
• W2885223211 hasAuthorship W2885223211A5071802884 @default.
• W2885223211 hasAuthorship W2885223211A5086841234 @default.
• W2885223211 hasAuthorship W2885223211A5089028589 @default.
• W2885223211 hasAuthorship W2885223211A5090126068 @default.
• W2885223211 hasConcept C185592680 @default.
• W2885223211 hasConcept C190283241 @default.
• W2885223211 hasConcept C2775975398 @default.
• W2885223211 hasConcept C2776241388 @default.
• W2885223211 hasConcept C2778484676 @default.
• W2885223211 hasConcept C29537977 @default.
• W2885223211 hasConcept C502942594 @default.
• W2885223211 hasConcept C55493867 @default.
• W2885223211 hasConcept C62112901 @default.
• W2885223211 hasConcept C86803240 @default.
• W2885223211 hasConcept C98274493 @default.
• W2885223211 hasConceptScore W2885223211C185592680 @default.
• W2885223211 hasConceptScore W2885223211C190283241 @default.
• W2885223211 hasConceptScore W2885223211C2775975398 @default.
• W2885223211 hasConceptScore W2885223211C2776241388 @default.
• W2885223211 hasConceptScore W2885223211C2778484676 @default.
• W2885223211 hasConceptScore W2885223211C29537977 @default.
• W2885223211 hasConceptScore W2885223211C502942594 @default.
• W2885223211 hasConceptScore W2885223211C55493867 @default.
• W2885223211 hasConceptScore W2885223211C62112901 @default.
• W2885223211 hasConceptScore W2885223211C86803240 @default.
• W2885223211 hasConceptScore W2885223211C98274493 @default.
• W2885223211 hasLocation W28852232111 @default.
• W2885223211 hasOpenAccess W2885223211 @default.
• W2885223211 hasPrimaryLocation W28852232111 @default.
• W2885223211 hasRelatedWork W2185175380 @default.
• W2885223211 hasRelatedWork W2358161411 @default.
• W2885223211 hasRelatedWork W2358890472 @default.
• W2885223211 hasRelatedWork W2362964312 @default.
• W2885223211 hasRelatedWork W2367667778 @default.
• W2885223211 hasRelatedWork W2374067319 @default.
• W2885223211 hasRelatedWork W2378241413 @default.
• W2885223211 hasRelatedWork W2383691845 @default.
• W2885223211 hasRelatedWork W2389507514 @default.
• W2885223211 hasRelatedWork W2955113018 @default.
• W2885223211 isParatext "false" @default.
• W2885223211 isRetracted "false" @default.
• W2885223211 magId "2885223211" @default.
• W2885223211 workType "article" @default.